The core value driver remains KT-621, Kymera’s STAT6-targeting program. “STAT6 remains [the] primary driver to the story,” ...

Meanwhile, Sanofi has selected a new clinical candidate from a five-year-old, $2 billion collaboration with Kymera focusing on MGD therapies that target IRAK4, being explored as a drug target for ...

KYMR has announced that partner Sanofi SNY will not advance the development of lead IRAK4 degrader KT-474. This setback was somewhat offset by KYMR’s announcement of an exclusive option and license ...

Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith Edmund Ingham Thu, Mar. 21, 2024 2 Comments ...

US biotech Kymera Therapeutics has begun a strategic collaboration with Sanofi to develop and market several drugs tackling immune-inflammatory disease, which could be worth up to $2 billion.

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

Sabic to close UK cracker, plastics recycler Novoloop raises funds, Kymera strikes molecular glue deal, and more ...

Labcorp (LH), and Gilead (GILD) rise as Supreme Court upholds right to free preventive care under Obamacare. Read more here.

UBS analyst Colin White maintained a Buy rating on Sanofi (SNYNF – Research Report) today. The company’s shares closed yesterday at $94.99. Don’t Miss TipRanks’ Half-Year ...